5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rao, A.; Heller, G.; Ryan, C. J.; VanderWeele, D. J.; Lewis, L. D.; Tan, A.; Watt, C.; Chen, R. C.; Kohli, M.; Barata, P. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • BAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC)
    Meeting Abstract

    Rosenberg, J. E.; Park, S. H.; Dao, T. V.; Castellano, D. E.; Li, J. R.; Mukherjee, S.; Howells, K.; Dry, H.; Lanasa, M. C.; Stewart, R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • PSMAddition: A phase 3 trial to compare treatment with (177)Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer
    Meeting Abstract

    Sartor, A. O.; Tagawa, S. T.; Saad, F.; De Bono, J. S.; Feng, F. Y.; Fizazi, K.; Sakharova, O. V.; Morris, M. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible
    Meeting Abstract

    Petrylak, D. P.; Flaig, T. W.; Mar, N.; Gourdin, T. S.; Srinivas, S.; Rosenberg, J. E.; Guseva, M.; Yu, Y.; Narayanan, S.; Hoimes, C. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma
    Meeting Abstract

    Powles, T.; Choueiri, T. K.; Burotto, M.; Escudier, B.; Bourlon, M. T.; Shah, A. Y.; Suárez, C.; Hamzaj, A.; Porta, C.; Hocking, C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Use of bone modifying agents for metastatic castrate-resistant prostate cancer
    Meeting Abstract

    Mitchell, A. P.; Mishra Meza, A.; Farooki, A.; Panageas, K.; Bach, P. B.; Lipitz-Snyderman, A.; Morris, M. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Motzer, R. J.; Albiges, L.; Choueiri, T. K.; Plimack, E. R.; Rini, B. I.; Suttner, L.; Yin, L.; Willemann-Rogerio, J.; Hammers, H. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Impact of primary tumor location on efficacy and safety of pembrolizumab (pembro) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) enrolled in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-045 trials
    Meeting Abstract

    O'Donnell, P. H.; Balar, A. V.; Castellano, D. E.; De Wit, R.; Vaughn, D. J.; Powles, T.; Vuky, J.; Lee, J. L.; Fradet, Y.; Bellmunt, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer
    Meeting Abstract

    Morris, M. J.; Sartor, A. O.; Wong, J. Y. C.; Max, S. I.; Xie, H.; Russell, M.; Divgi, C. R.; Patricia, D.; Avadhani, A. N.; Nordquist, L. T.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Favorable toxicity of chemoradiation for muscle-invasive bladder cancer in elderly, frail patients
    Meeting Abstract

    Moore, A.; Zhang, Z.; Bochner, B. H.; Donahue, T. F.; Rosenberg, J. E.; Iyer, G.; Funt, S. A.; Bajorin, D. F.; Teo, M. Y.; Aggen, D. H.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save